USPTO Examiner BOESEN AGNIESZKA - Art Unit 1648

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18412485ENTEROVIRUS MULTI-ANTIGEN EPITOPE FUSION PROTEIN, GENE, VACCINE, AND PREPARATION METHOD THEREOFJanuary 2024June 2024Allow500NoNo
18388792T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOFNovember 2023February 2024Allow310YesNo
18463276RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINESeptember 2023December 2023Allow310NoNo
18202596T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOFMay 2023October 2023Allow510NoNo
18314052STABILIZED INFLUENZA HEMAGGLUTININ STEM REGION TRIMERS AND USES THEREOFMay 2023December 2023Allow700NoNo
18169440STEROID ACID-BASED IMMUNOGEN ENHANCERSFebruary 2023April 2024Allow1410NoNo
18081782ANTI-HUMAN PAPILLOMAVIRUS (HPV) ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOFDecember 2022June 2024Allow1810NoNo
18065083DELIVERY OF RNA TO TRIGGER MULTIPLE IMMUNE PATHWAYSDecember 2022May 2023Allow510NoNo
18080101DELIVERY OF RNA TO TRIGGER MULTIPLE IMMUNE PATHWAYSDecember 2022May 2023Allow510YesNo
18080075DELIVERY OF RNA TO TRIGGER MULTIPLE IMMUNE PATHWAYSDecember 2022May 2023Allow510NoNo
18065089DELIVERY OF RNA TO TRIGGER MULTIPLE IMMUNE PATHWAYSDecember 2022May 2023Allow510NoNo
18080090DELIVERY OF RNA TO TRIGGER MULTIPLE IMMUNE PATHWAYSDecember 2022June 2023Allow610NoNo
18065109DELIVERY OF RNA TO TRIGGER MULTIPLE IMMUNE PATHWAYSDecember 2022May 2023Allow510NoNo
18065106DELIVERY OF RNA TO TRIGGER MULTIPLE IMMUNE PATHWAYSDecember 2022May 2023Allow510NoNo
18065069DELIVERY OF RNA TO TRIGGER MULTIPLE IMMUNE PATHWAYSDecember 2022May 2023Allow510NoNo
18065095DELIVERY OF RNA TO TRIGGER MULTIPLE IMMUNE PATHWAYSDecember 2022May 2023Allow510NoNo
18065111DELIVERY OF RNA TO TRIGGER MULTIPLE IMMUNE PATHWAYSDecember 2022May 2023Allow510NoNo
18065076DELIVERY OF RNA TO TRIGGER MULTIPLE IMMUNE PATHWAYSDecember 2022May 2023Allow510NoNo
18065100DELIVERY OF RNA TO TRIGGER MULTIPLE IMMUNE PATHWAYSDecember 2022May 2023Allow510NoNo
18080275T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOFDecember 2022July 2023Allow710YesNo
18064168ANTIGEN PRESENTING SCAFFOLDS FOR IMMUNE-CELL MANIPULATIONDecember 2022March 2024Allow1510NoNo
18063823Compositions and Methods for Antigen Targeting to CD180December 2022March 2024Allow1510NoNo
17990848METHOD FOR EVALUATION OF VIABILITY OF VIRUSES WITH LYMPHOTROPISM PROPERTIESNovember 2022January 2024Allow1410NoNo
17966954VIRUS AND ANTIGEN PURIFICATION AND CONJUGATIONOctober 2022March 2024Allow1710YesNo
17961005T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOFOctober 2022June 2023Allow810YesNo
17948008HPV EPITOPES TARGETED BY T CELLS INFILTRATING CERVICAL MALIGNANCIES FOR USE IN VACCINESSeptember 2022April 2024Abandon1910NoNo
17813445METHODS OF OPTIMIZING NUCLEOTIDE SEQUENCES ENCODING ENGINEERED INFLUENZA PROTEINSJuly 2022July 2023Allow1200NoNo
17867466ANTIBODIES THAT POTENTLY NEUTRALIZE HEPATITIS B VIRUS AND USES THEREOFJuly 2022November 2023Allow1610NoNo
17811250ROTAVIRUS VACCINESJuly 2022June 2023Allow1100NoNo
17854891PHARMACEUTICAL COMPOSITION COMPRISING BISPECIFIC ANTIBODY CONSTRUCTSJune 2022December 2023Abandon1710NoNo
17854205METHODS OF USING LOW DOSE VOLUME B-CELL EPITOPE COMPOSITIONS FOR INDUCING AN ANTIBODY IMMUNE RESPONSE IN HUMAN SUBJECTSJune 2022March 2024Allow2020NoNo
17854462METHODS FOR CONTINUOUSLY INACTIVATING A VIRUS DURING MANUFACTURE OF A PROTEINJune 2022February 2024Allow1920NoNo
17849392RSV IMMUNIZATION REGIMENJune 2022September 2023Allow1511NoNo
17847629MUMPS VIRUS AS A POTENTIAL ONCOLYTIC AGENTJune 2022November 2023Allow1610NoNo
17845583T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOFJune 2022November 2022Allow510NoNo
17831024T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOFJune 2022November 2022Allow510YesNo
17749973T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOFMay 2022August 2022Allow310YesNo
17742221ADENOVIRUS POLYNUCLEOTIDES AND POLYPEPTIDESMay 2022June 2023Allow1310NoNo
17738548STEROID ACID-BASED IMMUNOGEN ENHANCERSMay 2022January 2023Allow811YesNo
17661379HUMANIZED ANTI-CLAUDIN-1 ANTIBODIES AND USES THEREOFApril 2022May 2024Abandon2420NoNo
17685717COMPOSITIONS INCLUDING SBI ADJUVANTS AND METHODS OF USE THEREOFMarch 2022June 2023Allow1511NoNo
17578094T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOFJanuary 2022April 2022Allow300NoNo
17558852INFLUENZA VIRUS MUTANTS AND USES THEREFORDecember 2021January 2024Allow2520NoNo
17534659MULTIVALENT INFLUENZA NANOPARTICLE VACCINESNovember 2021October 2023Allow2210YesNo
17511762DELIVERY OF RNA TO TRIGGER MULTIPLE IMMUNE PATHWAYSOctober 2021January 2023Allow1511YesNo
17507113T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOFOctober 2021May 2022Allow710YesNo
17504002STABILIZED INFLUENZA HEMAGGLUTININ STEM REGION TRIMERS AND USES THEREOFOctober 2021February 2023Allow1600NoNo
17405748HUMANIZED INFLUENZA MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOFAugust 2021April 2024Allow3211YesNo
17405884MODIFIED HEPATITIS C VIRUS E2 GLYCOPROTEINS AND METHODS OF USE THEREOFAugust 2021December 2023Abandon2811NoNo
17385465IMMUNOGENETIC RESTRICTION ON ELICITATION OF ANTIBODIESJuly 2021July 2023Abandon2410NoNo
17375797INFLUENZA VACCINESJuly 2021April 2023Allow2110NoNo
17422835RECOMBINANT VARICELLA-ZOSTER VIRUS (VZV) VACCINEJuly 2021March 2024Allow3200NoNo
17369091INDUCE AND ENHANCE IMMUNE RESPONSES USING RECOMBINANT REPLICON SYSTEMSJuly 2021July 2023Allow2410NoNo
17352845MUTATIONS THAT CONFER GENETIC STABILITY TO ADDITIONAL GENES IN INFLUENZA VIRUSESJune 2021June 2023Allow2310NoNo
17349558GENETICALLY ENCODED POLYPEPTIDE FOR AFFINITY CAPTURE AND PURIFICATION OF BIOLOGICSJune 2021March 2023Allow2121YesNo
17324494HEPATITIS B VIRUS (HBV) VACCINES AND USES THEREOFMay 2021March 2023Allow2210NoNo
17323082Methods and Compositions for Inducing an Immune Response Against Hepatitis B Virus (HBV)May 2021October 2022Allow1700NoNo
17322604USE AND TREATMENT OF DI-AMINO ACID REPEAT-CONTAINING PROTEINS ASSOCIATED WITH ALSMay 2021February 2024Allow3300NoNo
17320046REMOVAL OF TARGET CELLS BY CIRCULATING VIRUS-SPECIFIC CYTOTOXIC T-CELLS USING MHC CLASS I COMPRISING COMPLEXESMay 2021May 2023Abandon2410NoNo
17316834RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINEMay 2021May 2023Allow2410NoNo
17234145CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING HERPES SIMPLEX VIRUSApril 2021July 2023Allow2710YesNo
17231782DETECTION METHODS EMPLOYING HCV CORE LIPID AND DNA BINDING DOMAIN MONOCLONAL ANTIBODIESApril 2021April 2022Allow1200NoNo
17200745METHODS OF IMPROVING VECTOR TRANSDUCTION EFFICIENCY INTO T LYMPHOCYTESMarch 2021December 2022Allow2110NoNo
17186941VACCINES FORMED BY VIRUS AND ANTIGEN CONJUGATIONFebruary 2021January 2023Allow2310NoNo
17176777T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOFFebruary 2021July 2021Allow520YesNo
17161997Immunogenic Compositions to Treat and Prevent Microbial InfectionsJanuary 2021September 2023Allow3221NoNo
17157335METHOD FOR EVALUATION OF VIABILITY OF VIRUSES WITH LYMPHOTROPISM PROPERTIESJanuary 2021July 2022Allow1810NoNo
17147137METHODS OF OPTIMIZING NUCLEOTIDE SEQUENCES ENCODING ENGINEERED INFLUENZA PROTEINSJanuary 2021April 2022Allow1500NoNo
17131104T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOFDecember 2020May 2022Allow1710NoNo
17251869ANION EXCHANGE CHROMATOGRAPHY FOR RECOMBINANT AAV PRODUCTIONDecember 2020April 2024Allow4010NoNo
16972367METHOD FOR EFFICIENTLY INDUCING ANTIBODY, ANTIBODY AND DETECTION SYSTEM FOR HEPATITIS VIRUSDecember 2020August 2022Allow2111NoNo
15734670MUTANT OF L1 PROTEIN OF HUMAN PAPILLOMAVIRUS TYPE 18December 2020May 2023Allow2911NoNo
17109851COMPOSITIONS AND RELATED METHODS FOR CONTROLLING VECTOR-BORNE DISEASESDecember 2020February 2024Allow3811NoNo
15734148HEPATITIS B VACCINE TRANSNASAL ADMINISTRATION SYSTEMDecember 2020April 2024Allow4010NoNo
17059934HEPATITIS B ANTIBODIESNovember 2020December 2023Allow3600NoNo
17100857METHOD FOR ROBUST CONTROL OF GENE EXPRESSIONNovember 2020June 2023Allow3110NoNo
17057230ECHO-7 ONCOLYTIC VIRUS FOR USE IN THE TREARMENT OF UVEAL MELANOMANovember 2020April 2024Abandon4110NoNo
17057489USE OF PROTEASOME INHIBITOR AND ALPHAVIRUS IN PREPARATION OF ANTI-TUMOR MEDICAMENTNovember 2020April 2024Abandon4010NoNo
16952864CONSTRUCTION OF WEST NILE VIRUS AND DENGUE VIRUS CHIMERAS FOR USE IN A LIVE VIRUS VACCINE TO PREVENT DISEASE CAUSED BY WEST NILE VIRUSNovember 2020May 2022Allow1810NoNo
17055817TREATMENT AND PREVENTION OF HOUSE DUST MITE ALLERGIESNovember 2020May 2023Allow3021NoNo
17052591USE FOR PREVENTING AND TREATING MYELOID-DERIVED SUPPRESSOR CELL-RELATED DISEASESNovember 2020June 2024Allow4310NoNo
17081124Humanized Anti-Claudin-1 Antibodies and Uses ThereofOctober 2020January 2022Allow1500NoNo
17071976SUBJECT ANTI-HCV ANTIBODY DETECTION ASSAYS EMPLOYING NS3 CAPTURE PEPTIDESOctober 2020January 2022Allow1600NoNo
17067929Use of CD24 Proteins for Treating Leptin-Deficient ConditionsOctober 2020July 2022Abandon2110NoNo
17046487AAV VECTORS ENCODING CLARIN-1 OR GJB2 AND USES THEREOFOctober 2020March 2024Allow4110NoNo
17045393METHOD FOR DETECTING NUCLEIC ACID BASED ON PROKARYOTIC ARGONAUTE PROTEIN AND APPLICATION THEREOFOctober 2020June 2024Allow4410NoNo
17043847NOVEL SALMONELLA TYPHIMURIUM BACTERIOPHAGE STP-2 AND USE THEREOF FOR INHIBITING PROLIFERATION OF SALMONELLA TYPHIMURIUMSeptember 2020March 2024Allow4210NoNo
17041784METHODS OF GENERATING BROADLY PROTECTIVE VACCINE COMPOSITIONS COMPRISING HEMAGGLUTININSeptember 2020September 2022Allow2411NoNo
17016246TREATMENT AND PREVENTION OF GENITAL WARTSSeptember 2020January 2024Abandon4001NoNo
17007095MARKER COMBINATIONS FOR DIAGNOSING INFECTIONS AND METHODS OF USE THEREOFAugust 2020December 2022Abandon2711NoNo
16992188ANTI-HUMAN PAPILLOMAVIRUS (HPV) ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOFAugust 2020September 2022Allow2500NoNo
16939266METHODS FOR COMBINING ADOPTIVE T CELL THERAPY WITH ONCOLYTIC VIRUS ADJUNCT THERAPYJuly 2020January 2023Allow3020YesNo
16919943VACCINES FORMED BY VIRUS AND ANTIGEN CONJUGATIONJuly 2020January 2023Allow3111NoNo
16957931MHC CLASS I ASSOCIATED PEPTIDES FOR PREVENTION AND TREATMENT OF MULTIPLE FLAVI VIRUSJune 2020February 2023Allow3230NoNo
16895958BINDING MOLECULES TARGETING PATHOGENSJune 2020August 2022Abandon2601NoNo
16884505HPV EPITOPES TARGETED BY T CELLS INFILTRATING CERVICAL MALIGNANCIES FOR USE IN VACCINESMay 2020May 2022Allow2420NoNo
16864087ANTIBODIES THAT POTENTLY NEUTRALIZE HEPATITIS B VIRUS AND USES THEREOFApril 2020November 2021Allow1900NoNo
16759898ANTI-CAR COMPOSITIONS AND METHODSApril 2020June 2024Abandon5011NoNo
16759670IMMUNOGENIC HETEROCLITIC PEPTIDES FROM CANCER-ASSOCIATED PROTEINS AND METHODS OF USE THEREOFApril 2020September 2024Abandon5321NoNo
16647705MULTIVALENT EPSTEIN-BARR VIRUS-LIKE PARTICLES AND USES THEREOFMarch 2020December 2023Allow4521NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BOESEN, AGNIESZKA.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
9
Examiner Affirmed
6
(66.7%)
Examiner Reversed
3
(33.3%)
Reversal Percentile
49.3%
Lower than average

What This Means

With a 33.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
69
Allowed After Appeal Filing
13
(18.8%)
Not Allowed After Appeal Filing
56
(81.2%)
Filing Benefit Percentile
23.4%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 18.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner BOESEN, AGNIESZKA - Prosecution Strategy Guide

Executive Summary

Examiner BOESEN, AGNIESZKA works in Art Unit 1648 and has examined 700 patent applications in our dataset. With an allowance rate of 52.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 34 months.

Allowance Patterns

Examiner BOESEN, AGNIESZKA's allowance rate of 52.9% places them in the 14% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by BOESEN, AGNIESZKA receive 2.11 office actions before reaching final disposition. This places the examiner in the 56% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by BOESEN, AGNIESZKA is 34 months. This places the examiner in the 42% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +33.2% benefit to allowance rate for applications examined by BOESEN, AGNIESZKA. This interview benefit is in the 81% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 22.2% of applications are subsequently allowed. This success rate is in the 27% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 37.9% of cases where such amendments are filed. This entry rate is in the 58% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 93% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 75.7% of appeals filed. This is in the 67% percentile among all examiners. Of these withdrawals, 67.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 78.1% are granted (fully or in part). This grant rate is in the 83% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 2.4% of allowed cases (in the 77% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 3.2% of allowed cases (in the 75% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.